000295921 001__ 295921
000295921 005__ 20241227115429.0
000295921 0247_ $$2doi$$a10.1007/s00520-024-09068-z
000295921 0247_ $$2pmid$$apmid:39694910
000295921 0247_ $$2ISSN$$a0941-4355
000295921 0247_ $$2ISSN$$a1433-7339
000295921 037__ $$aDKFZ-2024-02734
000295921 041__ $$aEnglish
000295921 082__ $$a610
000295921 1001_ $$aSweegers, Maike G$$b0
000295921 245__ $$aMetastatic breast cancer patients' preferences for exercise programs: a latent class analysis using data from a survey in five European countries.
000295921 260__ $$aNew York,NY$$bSpringer$$c2025
000295921 3367_ $$2DRIVER$$aarticle
000295921 3367_ $$2DataCite$$aOutput Types/Journal article
000295921 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1735296845_21519
000295921 3367_ $$2BibTeX$$aARTICLE
000295921 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000295921 3367_ $$00$$2EndNote$$aJournal Article
000295921 520__ $$aWe aimed to identify metastatic breast cancer (MBC) patients' preferences for exercise programs and identify patients' characteristics associated with these preferences, to facilitate implementation of exercise programs for MBC patients.We used data from a multinational cross-sectional survey conducted among MBC patients. Patients reported their preferred exercise frequency, intensity, type, session duration, and supervision mode. We used latent class analysis to identify subgroups with similar preferences and descriptive statistics to compare demographic and clinical characteristics of patients within subgroups.Four distinct classes were identified based on data from 409 participants. Class 1 (47% of participants) is characterized by a preference for moderate exercise with supervision within the health care setting. Most participants in this class had bone metastases. Class 2 (30%) is characterized by a preference for vigorous exercise with supervision. This class included participants who were, on average, younger, and had a higher education level. Class 3 (13%) is characterized by a preference for active walking. These participants were less likely to have bone metastases or comorbidities. Class 4 (10%) is characterized by a preference for recreational walking and included participants who were, on average, older, and less likely to be employed.We identified four classes of patients with different preferences for exercise programs. Many patients with MBC express exercise preferences that meet the current guideline recommendations. Some patients with MBC may benefit from targeted education to align their preferences and behavior with the amount of exercise that is necessary to gain health benefits.
000295921 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000295921 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000295921 650_7 $$2Other$$aExercise preferences
000295921 650_7 $$2Other$$aLatent class analysis
000295921 650_7 $$2Other$$aMetastatic breast cancer
000295921 650_7 $$2Other$$aPatient perspectives
000295921 650_2 $$2MeSH$$aHumans
000295921 650_2 $$2MeSH$$aFemale
000295921 650_2 $$2MeSH$$aBreast Neoplasms: pathology
000295921 650_2 $$2MeSH$$aCross-Sectional Studies
000295921 650_2 $$2MeSH$$aMiddle Aged
000295921 650_2 $$2MeSH$$aPatient Preference
000295921 650_2 $$2MeSH$$aEurope
000295921 650_2 $$2MeSH$$aAged
000295921 650_2 $$2MeSH$$aLatent Class Analysis
000295921 650_2 $$2MeSH$$aAdult
000295921 650_2 $$2MeSH$$aSurveys and Questionnaires
000295921 650_2 $$2MeSH$$aExercise Therapy: methods
000295921 650_2 $$2MeSH$$aBone Neoplasms: secondary
000295921 650_2 $$2MeSH$$aExercise: physiology
000295921 650_2 $$2MeSH$$aNeoplasm Metastasis
000295921 650_2 $$2MeSH$$aAge Factors
000295921 7001_ $$0P:(DE-He78)02b45d03ea9bc2c222c7aebf546803c5$$aDepenbusch, Johanna$$b1
000295921 7001_ $$aAaronson, Neil K$$b2
000295921 7001_ $$aHiensch, Anouk E$$b3
000295921 7001_ $$aWengström, Yvonne$$b4
000295921 7001_ $$aBackman, Malin$$b5
000295921 7001_ $$aGunasekara, Nadira$$b6
000295921 7001_ $$aClauss, Dorothea$$b7
000295921 7001_ $$aBelloso, Jon$$b8
000295921 7001_ $$aLachowicz, Milena$$b9
000295921 7001_ $$aMay, Anne M$$b10
000295921 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b11$$udkfz
000295921 7001_ $$aStuiver, Martijn M$$b12
000295921 773__ $$0PERI:(DE-600)1463166-0$$a10.1007/s00520-024-09068-z$$gVol. 33, no. 1, p. 39$$n1$$p39$$tSupportive care in cancer$$v33$$x0941-4355$$y2025
000295921 909CO $$ooai:inrepo02.dkfz.de:295921$$pVDB
000295921 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)02b45d03ea9bc2c222c7aebf546803c5$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000295921 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000295921 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000295921 9141_ $$y2024
000295921 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-21$$wger
000295921 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-21$$wger
000295921 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000295921 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000295921 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000295921 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000295921 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000295921 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000295921 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-21
000295921 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSUPPORT CARE CANCER : 2022$$d2023-10-21
000295921 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000295921 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000295921 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-21
000295921 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Präventionsforschung und Krebs$$x0
000295921 980__ $$ajournal
000295921 980__ $$aVDB
000295921 980__ $$aI:(DE-He78)C110-20160331
000295921 980__ $$aUNRESTRICTED